Atossa Genetics (NASDAQ:ATOS) Posts Quarterly Earnings Results, Meets Estimates

Atossa Genetics (NASDAQ:ATOS) posted its quarterly earnings results on Tuesday. The company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07), Zacks reports.

Atossa Genetics Price Performance

NASDAQ ATOS traded down $0.02 during mid-day trading on Wednesday, hitting $0.81. The stock had a trading volume of 341,886 shares, compared to its average volume of 861,516. The firm’s 50 day moving average is $0.90 and its 200 day moving average is $0.86. The stock has a market capitalization of $103.98 million, a price-to-earnings ratio of -3.50 and a beta of 0.99. Atossa Genetics has a twelve month low of $0.55 and a twelve month high of $1.52.

Analyst Ratings Changes

ATOS has been the subject of several analyst reports. Zacks Research cut Atossa Genetics from a “hold” rating to a “strong sell” rating in a report on Monday, October 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday, October 8th. Finally, Ascendiant Capital Markets boosted their price target on Atossa Genetics from $7.50 to $7.75 and gave the company a “buy” rating in a report on Monday, September 22nd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $6.25.

Institutional Trading of Atossa Genetics

Several large investors have recently bought and sold shares of the business. Ameriprise Financial Inc. purchased a new position in Atossa Genetics in the 2nd quarter worth approximately $2,468,000. Jane Street Group LLC purchased a new position in Atossa Genetics during the second quarter worth approximately $381,000. Qube Research & Technologies Ltd boosted its stake in Atossa Genetics by 357.4% during the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock worth $346,000 after buying an additional 325,340 shares during the last quarter. Vanguard Group Inc. grew its holdings in Atossa Genetics by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock valued at $5,270,000 after buying an additional 245,717 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in shares of Atossa Genetics by 51.3% in the 4th quarter. Bank of America Corp DE now owns 111,475 shares of the company’s stock worth $105,000 after acquiring an additional 37,809 shares during the last quarter. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Atossa Genetics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.